Comparison of platelet aggregation of ticagrelor 180 mg, clopidogrel 600 mg loading dose and prasugrel 60 mg loading dose and correlation of response of platelet aggregation to CYP2C19*2, *3, and *17 single nucleotide polymorphisms in Thai patients who planned undergoing coronary angiography.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Coronary disorders
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2017 New trial record